Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 416,742 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 268 · Balance 416,742 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 268 | $11.15 | $2,988.20 |
DisclosureSEC source: 0001654435-26-000003 · primarydocument.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,742 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. Read SEC document |
| December 31, 2025 Filed Jan 8, 2026 21:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1 | $10.99 | $10.99 |
DisclosureSEC source: 0001654435-26-000001 · primarydocument.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,474 F1 · security: The reporting person is reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2025. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 833 | $15.13 | $12,603.29 |
DisclosureSEC source: 0001562180-25-005187 · primarydocument.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,473 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:04 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000065 · primarydocument.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,640 F3 · shares: Represents restricted share units that are scheduled to vest in equal installments on December 31, 2025 and December 31, 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:04 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 412 | $14.75 | $6,076.18 |
DisclosureSEC source: 0001562180-25-000065 · primarydocument.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,640 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024. Read SEC document |
| June 28, 2024 Filed Aug 6, 2024 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,239 | $12.24 | $15,165.36 |
DisclosureSEC source: 0001562180-24-006041 · primarydocument.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,228 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 367 | $35.28 | $12,947.76 |
DisclosureSEC source: 0001562180-23-005755 · primarydocument.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,989 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 39 | $62.31 | $2,429.90 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 13 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,622 F11 · price: In accordance with the issuer's Employee Share Purchase Plan, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 187,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · derivative · entry 15 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 187,500 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. F12 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · derivative · entry 14 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. F12 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 187,500 | $108.00 | $20,250,000.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 12 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 187,500 | $7.15 | $1,340,625.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 11 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $119.99 | $59,993.50 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 10 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 F10 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 500 shares in multiple trades at prices ranging from $119.98 to $120.00. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,344 | $119.35 | $160,405.46 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 9 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 F9 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,344 shares in multiple trades at prices ranging from $118.95 to $119.84. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,123 | $118.47 | $251,514.78 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 8 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,427 F8 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,123 shares in multiple trades at prices ranging from $117.91 to $118.90. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 999 | $117.01 | $116,894.09 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 7 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 F7 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 999 shares in multiple trades at prices ranging from $116.85 to $117.82. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,395 | $116.06 | $161,906.21 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 6 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,549 F6 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,395 shares in multiple trades at prices ranging from $115.79 to $116.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,702 | $115.21 | $426,512.23 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,944 F5 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 3,702 shares in multiple trades at prices ranging from $114.79 to $115.78. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,568 | $114.35 | $522,361.76 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,646 F4 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,568 shares in multiple trades at prices ranging from $113.76 to $114.75. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,000 | $112.86 | $225,726.40 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,214 F3 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,000 shares in multiple trades at prices ranging from $112.29 to $113.26. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,369 | $111.23 | $930,915.67 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,214 F2 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 8,369 shares in multiple trades at prices ranging from $111.00 to $111.97. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $11.46 | $286,500.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 276 | $59.08 | $16,304.70 |
DisclosureSEC source: 0001645113-22-000062 · wf-form4_165723047506853.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:22 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 13,470 | $80.59 Strike: $80.59 | $1,085,547.30 |
DisclosureSEC source: 0001645113-22-000019 · wf-form4_164669531950813.xml · derivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,470 Underlying: Ordinary Shares · 13,470 shares Expires 2032-02-29 F1 · shares: Options to buy 13,470 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 22:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 31 | $63.82 | $1,978.36 |
DisclosureSEC source: 0001645113-22-000004 · wf-form4_164202669529935.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,307 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 104 | $96.50 | $10,036.00 |
DisclosureSEC source: 0001645113-21-000116 · wf-form4_163822248140323.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,276 Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 1,000 | $103.37 | $103,370.00 |
DisclosureSEC source: 0001645113-21-000116 · wf-form4_163822248140323.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,172 Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 3,870 | $102.36 | $396,133.20 |
DisclosureSEC source: 0001645113-21-000116 · wf-form4_163822248140323.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,172 F1 · price: On November 26, 2021, Mr. Danziger purchased 3,870 shares in multiple trades at prices ranging from $102.00 to $102.60. The price reported above reflects the weighted average purchase price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 118 | $137.12 | $16,180.40 |
DisclosureSEC source: 0001645113-21-000084 · wf-form4_162577981023454.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,302 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:01 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 97,973 | $196.34 | $19,236,322.54 |
DisclosureSEC source: 0001645113-21-000055 · wf-form4_161852408765067.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,184 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 9,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000024 · wf-form4_161471980303632.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,259 | $149.10 | $1,380,516.90 |
DisclosureSEC source: 0001645113-21-000024 · wf-form4_161471980303632.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 53 | $50.67 | $2,685.46 |
DisclosureSEC source: 0001645113-21-000001 · wf-form4_161014142054692.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,685 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2020 through December 31, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 103,955 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · derivative · entry 27 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 103,955 shares Expires 2025-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F24 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 103,955 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · derivative · entry 26 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,955 Underlying: Ordinary Shares · 103,955 shares Expires 2025-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F24 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $166.08 | $66,431.60 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 25 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,632 F23 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 400 shares in multiple trades at prices ranging from $165.97 to $166.12. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 971 | $164.96 | $160,175.19 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 24 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,032 F22 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 971 shares in multiple trades at prices ranging from $164.52 to $165.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 536 | $163.35 | $87,554.53 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 23 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,003 F21 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 536 shares in multiple trades at prices ranging from $163.25 to $163.60. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,700 | $162.35 | $276,000.10 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 22 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,539 F20 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,700 shares in multiple trades at prices ranging from $161.81 to $162.80. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,014 | $161.11 | $646,679.48 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 21 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,239 F19 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,014 shares in multiple trades at prices ranging from $160.78 to $161.76. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,686 | $160.27 | $1,872,915.22 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 20 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,253 F18 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 11,686 shares in multiple trades at prices ranging from $159.76 to $160.72. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,790 | $159.27 | $762,903.30 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 19 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,939 F17 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,790 shares in multiple trades at prices ranging from $158.72 to $159.63. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,077 | $158.06 | $1,592,810.93 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 18 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,729 F16 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 10,077 shares in multiple trades at prices ranging from $157.64 to $158.60. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 23,601 | $157.01 | $3,705,522.21 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 17 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,806 F15 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 23,601 shares in multiple trades at prices ranging from $156.63 to $157.61. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 24,973 | $156.08 | $3,897,860.76 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 16 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,407 F14 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 24,973 shares in multiple trades at prices ranging from $155.63 to $156.62. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 21,207 | $155.23 | $3,292,005.02 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 15 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,380 F13 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 21,207 shares in multiple trades at prices ranging from $154.63 to $155.60. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 103,955 | $22.00 | $2,287,010.00 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 14 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $166.17 | $33,234.40 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 13 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,632 F12 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 200 shares in multiple trades at prices ranging from $165.97 to $166.38. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 700 | $165.38 | $115,768.10 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 12 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,832 F11 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 700 shares in multiple trades at prices ranging from $164.90 to $165.75. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $164.11 | $82,054.50 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 11 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,532 F10 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 500 shares in multiple trades at prices ranging from $163.82 to $164.53. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.